Skip to main content

Table 2 Response of HBeAg-positive patients to various doses and duration of PEG-IFN alfa-2a therapy analyzed according to endpoint

From: Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Dose/Duration and endpoint

EOT

Time after end of treatment (years)

0.5

1

2

3

4

5

90 μg / 24 week

ALT normalization

1/4

0/4

0/4

0/4

0/4

0/4

0/4

HBeAg seroconversion

0/4

0/4

0/4

0/4

0/4

0/4

0/4

Low HBV (<5 log copies/mL)

0/4

0/4

0/4

0/4

0/4

0/4

0/4

180 μg / 24 week

ALT normalization

0/4

0/4

0/4

1/4

0/3

0/3

0/3

HBeAg seroconversion

0/4

0/4

1/4

1/4

0/3

0/3

0/3

Low HBV (<5 log copies/mL)

2/4

0/4

1/4

2/4

0/3

0/3

0/3

90 μg/48 week

ALT normalization

0/4

2/4

1/3

2/3

1/3

2/3

2/3

HBeAg seroconversion

1/4

1/4

1/3

2/3

2/3

2/3

2/3

Low HBV (<5 log copies/mL)

1/4

2/4

1/3

2/3

2/3

2/3

2/3

180 μg/48 week

ALT normalization

1/5

3/5

2/5

2/5

2/4

1/4

1/4

HBeAg seroconversion

3/5

3/5

2/5

1/5

1/4

1/4

1/4

Low HBV (<5 log copies/mL)

4/5

1/5

1/5

1/5

1/4

1/4

1/4

  1. EOT end of treatment